

Media Release

14 December 2022

PHARMAXIS APPOINTS DR SIMON GREEN AS DIRECTOR

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) is pleased to announce the appointment of experienced senior global pharma executive Dr Simon Green to the Board as an independent non-executive director.

Dr Green has 30 years of experience in the biotechnology industry focussed on the discovery, development and commercialisation of life saving medicines. He worked in the USA at leading biotechnology companies Genentech Inc and Chiron Corporation prior to joining CSL in 1998. Dr Green was actively involved in CSL's global expansion over a 17-year period and held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL's manufacturing plants in Germany and Australia.

Dr Green's breadth of skills covers R&D drug development, corporate due diligence, mergers and acquisitions, strategic planning, portfolio management, financial management, intellectual property management, business development, contract management and organizational design.

Dr Green was educated at Monash University (Bachelor's Degree with Honours) and the University of Melbourne (Doctor of Philosophy, Biochemistry and Immunology). He is a graduate of the Australian Institute of Company Directors Company Directors Course.

Pharmaxis Chairman Malcolm McComas said, "We are delighted to welcome Simon to the Pharmaxis Board. He is an innovator with a strong drive to improve the lives of patients and his deep experience in product development at CSL is very relevant to our near term plans for the commercialization of our drug candidates for myelofibrosis and other fibrotic diseases."

Dr Green said, "I look forward to contributing to the pipeline of exciting new products at Pharmaxis. The company has an impressive team, excellent facilities and an exciting portfolio of commercially attractive product candidates for the treatment of diseases with serious unmet medical needs."

Dr Green is a non-executive director of Clover Corporation Limited (ASX: CLV) and is the founder and CEO of Immunosis Pty Ltd, a start-up diagnostics Company. He is also a Venture Partner and investment advisor at BioScience Managers, a healthcare investment firm and serves on the scientific advisory board for Immunex Pty Ltd.

Dr Green is based in Melbourne Australia and will take up his role as non-executive director on 16 December 2022.

#ENDS#

SOURCE: Pharmaxis Ltd, Sydney, Australia

AUTHORISED FOR RELEASE TO ASX BY:

Pharmaxis Ltd Disclosure Committee. Contact: David McGarvey, Chief Financial Officer and Company Secretary: T +61 2 9454 7203, E david.mcgarvey@pharmaxis.com.au

CONTACT:

Media: Felicity Moffatt: T +61 418 677 701, E felicity.moffatt@pharmaxis.com.au

Investor relations: Rudi Michelson (Monsoon Communications) T +61 411 402 737, E rudim@monsoon.com.au

Join the Pharmaxis mailing list [here](#)

Follow us:



About Pharmaxis

Pharmaxis Ltd is an Australian clinical stage drug development company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The company has a highly productive drug discovery engine built on its expertise in the chemistry of amine oxidase inhibitors, with drug candidates in clinical trials. Pharmaxis has also developed two respiratory products which are approved and supplied in global markets, generating ongoing revenue.

Pharmaxis is developing its drug PXS-5505 for the bone marrow cancer myelofibrosis which causes a build up of scar tissue that leads to loss of production of red and white blood cells and platelets. The US Food and Drug Administration has granted Orphan Drug Designation to PXS-5055 for the treatment of myelofibrosis and permission under an Investigational Drug Application (IND) to progress a phase 1c/2 clinical trial that began recruitment in Q1 2021. PXS-5505 is also being investigated as a potential treatment for other cancers such as liver and pancreatic cancer. The FDA has granted an IND for a phase 1c/2a clinical trial in liver cancer.

Other drug candidates being developed from Pharmaxis' amine oxidase chemistry platform are targeting fibrotic diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis; fibrotic scarring from burns and other trauma; and other inflammatory diseases. PXS-4728 is being studied in collaboration with Parkinson's UK as a best in class SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Pharmaxis has developed two products from its proprietary spray drying technology that are manufactured and exported from its Sydney facility; Bronchitol® for cystic fibrosis, which is approved and marketed in the United States, Europe, Russia and Australia; and Aridol® for the assessment of asthma, which is approved and marketed in the United States, Europe, Australia and Asia.

Pharmaxis is listed on the Australian Securities Exchange (PXS). Its head office, manufacturing and research facilities are in Sydney, Australia. www.pharmaxis.com.au

Forward-looking statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.